What is it used for?
CAMZYOS® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.CAMZYOS® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- mavacamtenmavacamten
- Form and strength
- CAPSULE, GELATIN COATED · 2.5 mg; CAPSULE, GELATIN COATED · 5 mg; CAPSULE, GELATIN COATED · 10 mg; CAPSULE, GELATIN COATED · 15 mgCAPSULE, GELATIN COATED · 2.5 mg; CAPSULE, GELATIN COATED · 5 mg; CAPSULE, GELATIN COATED · 10 mg; CAPSULE, GELATIN COATED · 15 mg
- Manufacturer / applicant
- MYOKARDIA, INC.MYOKARDIA, INC.
CAMZYOS is available as capsules imprinted with the strength and “Mava” in the following strengths: •2.5 mg – light purple cap •5 mg – yellow cap •10 mg – pink cap •15 mg – gray capCAMZYOS is available as capsules imprinted with the strength and “Mava” in the following strengths: •2.5 mg – light purple cap •5 mg – yellow cap •10 mg – pink cap •15 mg – gray cap
Safety and clinical review
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction . Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt …CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction . Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt …
- Heart FailureHeart Failure
- CYP450 Drug Interactions Leading to Heart Failure or Loss of EffectivenessCYP450 Drug Interactions Leading to Heart Failure or Loss of Effectiveness
- CAMZYOS REMS ProgramCAMZYOS REMS Program
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Camzyos used for?
CAMZYOS® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.CAMZYOS® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Camzyos should I ask about?
CAPSULE, GELATIN COATED · 2.5 mg; CAPSULE, GELATIN COATED · 5 mg; CAPSULE, GELATIN COATED · 10 mg; CAPSULE, GELATIN COATED · 15 mgCAPSULE, GELATIN COATED · 2.5 mg; CAPSULE, GELATIN COATED · 5 mg; CAPSULE, GELATIN COATED · 10 mg; CAPSULE, GELATIN COATED · 15 mg
Read the primary sourceWhat determines the price of Camzyos?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Camzyos?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.